STAAR Surgical is a standalone refractive-lens company again after shareholders rejected Alcon's raised cash bid in January, and the quarter ended in early July is the first clean look at whether that independence was earned. Last year was defined by China destocking, a contested sale process, and a leadership reset forced by the largest holder. This print shows procedure demand returning and the newer EVO Plus lens taking share from laser surgery. The equity still trades well below the cash value that the special-meeting vote turned down.
China produced more than half of quarterly sales and almost all of the year-over-year jump, while sales outside China rose only in the mid-single digits. Trade receivables roughly doubled from the start of the fiscal year as two China distributors again dominate the book. Gross margin held in the mid-seventies even with tariffs on American-made lenses still in the mix. The swing back to operating profit is genuine. It also sits on a concentration that last year's destock already proved can erase years of compounding in a single channel cycle.
The next two prints resolve whether China share gains survive a seasonal step-down and whether the Swiss plant finishes the tariff exit. Last year's third quarter included a $26 million non-recurring China shipment that does not repeat. The live question is whether standalone STAAR is a share-taking platform or a destock bounce still priced as if the rejected bid were the ceiling.